ProQR Therapeutics (PRQR) Net Cash Flow (2013 - 2026)

ProQR Therapeutics (PRQR) has reported Net Cash Flow for 14 consecutive years, with -$13.6 million the latest figure, recorded in Q1 2026.

• Quarterly Net Cash Flow rose 30.22% year-over-year to -$13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.8 million (down 225.07% YoY) and the FY2025 annual result came in at -$65.4 million, down 311.72% from the prior year.
• Net Cash Flow advanced to -$13.6 million in Q1 2026 per PRQR's latest filing, from -$18.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for PRQR reached as high as $64.4 million in Q4 2024 and fell as low as -$67.6 million in Q3 2022.
• A 5-year average of -$8.1 million and a median of -$13.6 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 487.24% — and 2024, when it soared 16750.0%.
• Year by year, Net Cash Flow stood at -$4.6 million in 2022, then soared by 108.3% to $382352.6 in 2023, then surged by 16750.0% to $64.4 million in 2024, then tumbled by 128.75% to -$18.5 million in 2025, then increased by 26.69% to -$13.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$13.6 million, -$18.5 million, and -$14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.